17,261 trials
Post-Operative Atrial Fibrillation
Primary: Percentage of Participants With at Least 1 Continuous AF (Atrial Fibrillation or Atrial Flutter) Episode ≥ 30 Seconds During the First 30 Days Post-surgery — 46.1; 36.5…
Degenerative Disc Disease
Primary: Transfusion — 7; 6; 9; 8 Participants
Perinatal Arterial Ischemic Stroke · Neonatal Stroke
Primary: Number of Participants With Adverse Events Related to Intranasal MSC Treatment (Safety and Tolerability) in the Acute Setting. — 10; 0; 9; 1 Participants
Hyperammonemia
Primary: Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) — 6; 6; 7; 8 participants
Respiratory Viral Infection · Antiviral Treatment · COVID-19
Primary: Number of Participants With Viral Illness — 12; 30 Participants
Small Cell Lung Carcinoma · Non Small Cell Lung Carcinoma · Irinotecan Sensitive Cancers
Primary: Phase Ib: Maximum Tolerated Dose — 20; 36 mg/m^2 Carfilzomib
Atopic Dermatitis
Primary: Number of Participants With Investigator Global Assessment (IGA) Response — 5; 2; 0; 0 Participants
Cancer · Solid Tumor
Primary: Overall Response Rate of Lenvatinib and Eribulin (Phase II) — 7; 13; 3 participants
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
IOP · Osteoporosis
Primary: Difference in BMD at the Lumbar Spine (L1-4) Within Group — -1.1; -2.4 percentage of change
Hematological Malignancies
Primary: Treatment-related Adverse Events — 4 Participants
Recurrent Childhood Ependymoma
Primary: Objective Response Rate (Complete Response Rate and Partial Response Rate) Following Treatment With Everolimus for Children With Recurrent or Progressive Ependymomas…
Cirrhosis · Hepatic Encephalopathy
Primary: Number of Participants Who Experienced Serious Adverse Events up to Week 6 — 2; 0 Participants
Neurotrophic Keratopathy
Primary: Mean Change From Baseline in Corneal Fluorescein Staining — -0.6; -0.9 score on a scale
Diabetes Mellitus, Type 2
Primary: Area Under the Curve (AUC(0-16)) of Endogenous Glucose Production — 3436.8; 3139.3 mg*hr/dL — p=0.1628